Phase 3 Readout
AZN: Phase 3 Topline: A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of C
June 30, 2026 · durvalumab. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 30, 2026
- Company
- ASTRAZENECA PLC (AZN)
- Drug
- durvalumab
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of C
- Company
- ASTRAZENECA PLC (AZN)
- Drug
- durvalumab
- Indication
- Non Small Cell Lung Carcinoma NSCLC
Other upcoming events for AZN
Phase 3 ReadoutPhase 3 Topline: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoe
Phase 3 ReadoutPhase 3 Topline: A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemothera
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combinati
Phase 3 ReadoutPhase 3 Topline: A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line
Phase 3 ReadoutPhase 3 Topline: A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compa